10-K: Wellgistics Health Releases Code of Ethics and Annual Report, Outlines Growth Strategy

Wellgistics Health, a holding company focused on pharmaceuticals and healthcare services, releases its Code of Business Conduct and Ethics and its annual report, detailing its business strategy and financial performance for the year ended December 31, 2024.

Summary

• Wellgistics Health, incorporated in 2022, aims to be a micro health ecosystem centered around pharmaceuticals and healthcare services.
• The company conducts business through its subsidiaries: Wood Sage LLC, Wellgistics LLC, Wellgistics Tech & Hub, LLC (DelivMeds), and Wellgistics Pharmacy, LLC.
• Key acquisitions include Wood Sage in June 2024 and Wellgistics LLC in August 2024, expanding the company's capabilities in technology, wholesale operations, and pharmacy services.
• The company focuses on specialty-lite pharmaceutical products and services, aiming to improve patient outcomes and provide value to pharmacies, providers, pharmaceutical manufacturers, and payors.
• Wellgistics Health's strategy involves a 5P-Model, focusing on Patients, Providers, Pharmacies, Payors/PBMs, and Pharmaceutical Manufacturing Companies.
• The company's revenue model is based on prescription fulfillment, wholesale distribution, and technology platform services.
• For the year ended December 31, 2024, Wellgistics Health reported net sales of $18,128,831 and a net loss of $6,856,226.
• The company is subject to various risks, including competition, regulatory changes, and economic conditions.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company outlines a comprehensive growth strategy and has made key acquisitions, it also reports a net loss and faces various risks and challenges.

Positives

• The company has a comprehensive strategy to leverage its subsidiaries to provide value to all stakeholders in the healthcare delivery model.
• The company's technology platform, DelivMeds, aims to improve price transparency and medication adherence.
• The company's wholesale operations serve over 5,000 registered pharmacies nationwide.
• Wellgistics Pharmacy is licensed in 32 states and the District of Columbia.

Negatives

• For the year ended December 31, 2024, Wellgistics Health reported a net loss of $6,856,226.
• The company has a substantial amount of goodwill and other intangible assets which could, in the future, become impaired and result in material non-cash charges to Wellgistics Healths results of operations.
• The company is subject to various risks, including competition, regulatory changes, and economic conditions.

Risks

• The company faces intense competition in the pharmacy, healthcare, and pharmaceutical wholesale industries.
• Regulatory changes in the healthcare industry could adversely affect the company's business.
• The company's success depends on its ability to manage organizational change and achieve cost savings.
• Disruptions in the global supply chain could negatively impact the company's businesses.
• The company's business is primarily focused on certain therapeutic targets, making it vulnerable to risks associated with having therapeutically concentrated operations.
• The company may not be able to maintain business, scale for growth, renew pharmacy and wholesale state licenses, and retain commercial and federal contracts while preventing restrictions and termination.
• The company may experience cybersecurity incidents and might experience significant computer system compromises or data breaches.
• The company has a substantial amount of debt which may negatively impact its liquidity, restrict its operations and ability to respond to business opportunities, and increase its vulnerability to adverse economic and industry conditions.

Future Outlook

The company expects to generate positive cash flow from operations in 2025 and may need to raise additional funds through debt or equity issuances.

Management Comments

• The company seeks to be a micro health ecosystem, with a portfolio of companies consisting of a pharmacy, wholesale operations, and a technology division that provides a novel platform for hub and clinical services.
• The company is focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.

Industry Context

The company operates in the highly competitive and evolving healthcare industry, which is subject to significant changes and regulatory pressures.

Comparison to Industry Standards

• The document mentions IQVIA's 2024 report on medicine spending trends, indicating that overall spending in the U.S. market for medicines reached $435 billion in 2023.
• The document references the Centers for Medicare & Medicaid Services data, illustrating that the National Health Expenditure Data for 2022 grew to $4.5 trillion dollars and accounted for 17.3% of GDP.
• The document references a 2019 study performed by NACDS entitled Cost of Dispensing Study found that the overall cost of dispensing for all drugs was $12.40 per fill.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in a legal dispute with First Defense Nasal Screen Corp (FDNS), which has been settled where the Company was awarded $ 4.6 million.

Related Party Transactions

• The company had transactions with Scienture Holdings, Inc. and group (f/k/a/ TrXade Health, Inc / TRG / TrXade Health / Scienture). and group which included Integra Pharma Solutions, LLC (IPS), in which the board members of the Company are currently the management.
• Wellgistics, LLC. was previously partly owned by a private equity company, Nomad Capital, which has ownership interest in a few portfolio companies and Wellgistics, LLC. had transactions with some of the affiliated companies of Nomad Capital.
• The Company had transactions with Scietech, LLC. where a 31 % investor is the spouse of one of the Directors of the Company, which qualifies as a related party.
• The Company also had transactions with Green Apotoker, LLC. which qualifies as a related party on account of a managerial personnel of the Company having a significant influence.

Stakeholder Impact

• The company's strategy aims to improve patient outcomes and provide value to pharmacies, providers, pharmaceutical manufacturers, and payors.
• The company's focus on medication adherence and price transparency could benefit patients.
• The company's partnerships with group purchasing organizations could increase the visibility of its business divisions with member pharmacies.

Next Steps

• The company intends to expand its wholesale activities by continuing to partner with existing, and establishing new, manufacturer relationships.
• The company intends to actively monitor the drug pipeline and maintain dialogue with a significant number of biotechnology and pharmaceutical manufacturers to identify opportunities in preand peri-commercial stages of drug development.

Key Dates

Keywords

pharmaceuticals, healthcare, wholesale, pharmacy, DelivMeds, Wellgistics, specialty-lite, distribution, technology, PBMs